AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.

Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.

The REMS program investigated the safety and efficacy of mavacamten, a cardiac myosin inhibitor approved by the US FDA, which was monitored in over 5,500 symptomatic obstructive HCM patients. The primary outcome measure was the development of systolic heart failure and reduction of left ventricular ejection fraction.

Interview Questions:

1. What is the reasoning and data collection design behind the REMS program with mavacamten?
2. How do these results complement the REMS program?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.